NICE Recommends Alexion’s Soliris for Rare Blood Disorder

Drug Industry Daily
The UK’s drug pricing watchdog is recommending Alexion’s blood disease drug Soliris for a life-threatening blood disorder that affects roughly 200 people in England, although the agency is urging the National Health Service and the company to find ways of reducing the high cost of treatment.

To View This Article:


Subscribe To Drug Industry Daily